Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy-related acute myeloid leukemia with KMT2A-SNX9 gene fusion associated with a hyperdiploid karyotype after hemophagocytic lymphohistiocytosis.
Sardou-Cezar I, Lopes BA, Andrade FG, Fonseca TCC, Fernandez TS, Larghero P, de Souza RQ, Loth G, Ribeiro LL, Bonfim C, Morgado ES, Marschalek R, Meyer C, Pombo-de-Oliveira MS. Sardou-Cezar I, et al. Among authors: meyer c. Cancer Genet. 2021 Aug;256-257:86-90. doi: 10.1016/j.cancergen.2021.05.001. Epub 2021 May 7. Cancer Genet. 2021. PMID: 34034210
KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.
Assaf N, Liévin R, Merabet F, Raggueneau V, Osman J, Kim R, Garnache F, D'Angiò M, Larghero P, Meyer C, Marschalek R, Rousselot P, Terré C. Assaf N, et al. Among authors: meyer c. Mol Biol Rep. 2021 Oct;48(10):7021-7027. doi: 10.1007/s11033-021-06621-5. Epub 2021 Aug 12. Mol Biol Rep. 2021. PMID: 34383244 Review.
The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome.
Külp M, Larghero P, Alten J, Cario G, Eckert C, Caye-Eude A, Cavé H, Schmachtel T, Bardini M, Cazzaniga G, De Lorenzo P, Valsecchi MG, Bonig H, Meyer C, Rieger MA, Marschalek R. Külp M, et al. Among authors: meyer c. Leukemia. 2023 Jun;37(6):1216-1233. doi: 10.1038/s41375-023-01895-z. Epub 2023 Apr 26. Leukemia. 2023. PMID: 37100882 Free PMC article.
KMT2A-MLLT1 and the Novel SEC16A-KMT2A in a Cryptic 3-Way Translocation t(9;11;19) Present in an Infant With Acute Lymphoblastic Leukemia.
de Matos RRC, Ferreira GM, Meyer C, Marschalek R, Larghero P, Ribeiro RC, Liehr T, Othman M, Bizarro MTSM, Sobral da Costa E, Land MGP, Abdelhay E, Binato R, Silva MLM. de Matos RRC, et al. Among authors: meyer c. J Pediatr Hematol Oncol. 2022 Apr 1;44(3):e719-e722. doi: 10.1097/MPH.0000000000002386. J Pediatr Hematol Oncol. 2022. PMID: 34966090
Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.
Maurer-Granofszky M, Kohrer S, Fischer S, Schumich A, Nebral K, Larghero P, Meyer C, Mecklenbrauker A, Muhlegger N, Marschalek R, Haas OA, Panzer-Grumayer R, Dworzak MN. Maurer-Granofszky M, et al. Among authors: meyer c. Haematologica. 2024 Mar 1;109(3):740-750. doi: 10.3324/haematol.2022.282424. Haematologica. 2024. PMID: 37345487 Free PMC article.
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias.
Lopes BA, Poubel CP, Teixeira CE, Caye-Eude A, Cavé H, Meyer C, Marschalek R, Boroni M, Emerenciano M. Lopes BA, et al. Among authors: meyer c. Front Pharmacol. 2022 Jun 6;13:749472. doi: 10.3389/fphar.2022.749472. eCollection 2022. Front Pharmacol. 2022. PMID: 35734412 Free PMC article.
5,510 results